Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 4/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | THRA | P10827 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30394731 | 0.85 | SMN1; SMN2 (0.53) | SMN1; SMN2GAAALDH1A1TSHRHSD17B10 | |
| SCHEMBL30250609 | 0.83 | TSHR (0.52) | SMN1; SMN2GAAALDH1A1TSHRHSD17B10 | |
| SCHEMBL8085160 | 0.82 | HPGD (0.62) | SMN1; SMN2GAAALDH1A1HSD17B10KMT2A | |
| SCHEMBL1201453 | 0.75 | PLA2G2A (0.66) | ALDH1A1TSHRHPGD | |
| SCHEMBL1200906 | 0.75 | PLA2G2A (0.66) | ALDH1A1TSHRHPGD | |
| SCHEMBL10497889 | 0.75 | SMPD1 (0.50) | ALDH1A1THRBTHRAHPGD | |
| SCHEMBL1108057 | 0.75 | PLA2G2A (0.66) | ALDH1A1TSHRHPGD | |
| SCHEMBL318045 | 0.75 | PLA2G2A (0.66) | ALDH1A1TSHRHPGD | |
| SCHEMBL1200970 | 0.75 | PLA2G2A (0.66) | ALDH1A1TSHRHPGD | |
| SCHEMBL1108059 | 0.75 | PLA2G2A (0.66) | ALDH1A1TSHRHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113717239-B | Precipitation accelerator and precipitation method using the same | 味之素株式会社 | 2024-12-24 | — | — | CN | disclosed |
| EP-3263579-B1 | PRECIPITATION PROMOTER AND PRECIPITATION METHOD IN WHICH SAME IS USED | AJINOMOTO KK (JP) | 2022-11-30 | — | — | EP | disclosed |
| EP-4049991-A1 | PRECIPITATION PROMOTER AND PRECIPITATION METHOD IN WHICH SAME IS USED | AJINOMOTO CO., INC. (JP) | 2022-08-31 | — | — | EP | disclosed |
| US-10464966-B2 | Precipitation promoter and precipitation method in which same is used | AJINOMOTO CO., INC. (JP) | 2019-11-05 | — | — | US | disclosed |
| EP-3263579-A1 | PRECIPITATION ACCELERATOR AND PRECIPITATION METHOD IN WHICH SAME IS USED | AJINOMOTO CO., INC. (JP) | 2018-01-03 | — | — | EP | disclosed |
| US-20170320904-A1 | PRECIPITATION PROMOTER AND PRECIPITATION METHOD IN WHICH SAME IS USED | AJINOMOTO CO., INC. (JP) | 2017-11-09 | — | — | US | disclosed |
| US-20170320904-A1 | PRECIPITATION PROMOTER AND PRECIPITATION METHOD IN WHICH SAME IS USED | AJINOMOTO CO., INC. (JP) | 2017-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170320904-A1 | PRECIPITATION PROMOTER AND PRECIPITATION METHOD IN WHICH SAME IS USED | SP1, MED25, CTCF | SMN1; SMN2 4715/4885GAA 2265/4885ALDH1A1 2282/4885 |
| US-10464966-B2 | Precipitation promoter and precipitation method in which same is used | SP1, MED25, CTCF | SMN1; SMN2 4715/4885GAA 2265/4885ALDH1A1 2282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.